Drug-induced hypersensitivity syndrome: Clinical and biologic disease atterns in 24 patients

Medicine

Volumn 88, Issue 3, 2009, Pages 131-140

  Ben M'Rad, Mona ^a,b,e   Leclerc Mercier, St́phanie ^b   Blanche, Philippe ^a   Franck, Nathalie ^b   Rozenberg, Flore ^b   Fulla, Yvonne ^b   Guesmi, Myriam ^b   Rollot, Florence ^a   Dehoux, Monique ^c   Guillevin, Loïc ^a,b   Moachon, Laurence ^b,d  

^a Necrotizing Vasculitides and Systemic Sclerosis   (France)

^b université Paris Cité   (France)

^c BICHAT HOSPITAL   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e HÔPITAL AMBROISE PARÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALLOPURINOL; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATOVAQUONE PLUS PROGUANIL; AZATHIOPRINE; BORTEZOMIB; C REACTIVE PROTEIN; CALCIFEDIOL; CARBAMAZEPINE; CARBIMAZOLE; CHLOROQUINE PLUS PROGUANIL; CORTICOSTEROID; COTRIMOXAZOLE; CYTARABINE; FANSIDAR; FERRITIN; GLUCOCORTICOID; HYDROXYUREA; IMATINIB; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 18; LACTATE DEHYDROGENASE; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; PYRIMETHAMINE; SALAZOSULFAPYRIDINE; SULFADOXINE; UNINDEXED DRUG; VANCOMYCIN;

ADULT; ADULT ONSET STILL DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONVALESCENCE; CORTICOSTEROID THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRESS SYNDROME; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; EOSINOPHILIA; ERYTHROPHAGOCYTOSIS; FEMALE; FERRITIN BLOOD LEVEL; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER; MALE; MULTIPLE ORGAN FAILURE; MYOCARDITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RASH; RISK FACTOR; SKIN; SURVIVAL RATE; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; WINTER; AGED; BLOOD; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; HEMATOLOGIC DISEASE; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; CALCIFEDIOL; CARDIOVASCULAR DISEASES; COHORT STUDIES; DRUG HYPERSENSITIVITY; EOSINOPHILIA; FEMALE; GLUCOCORTICOIDS; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; VITAMIN D DEFICIENCY; YOUNG ADULT;

EID: 66349097529     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/MD.0b013e3181a4d1a1     Document Type: Article

References (94)

1. Abdel-Aty H, Boye P, Zagrosek A, Wassmuth R, Kumar A, Messroghli D, Bock P, Dietz R, Friedrich MG, Schulz-Menger J. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis. J Am Coll Cardiol. 2005;45:1815-1822.
2. Arlet JB, Le Thi Huong DB, Marinho A, Amoura Z, Wechsler B, Papo T, Piette JC. Reactive haemophagocytic syndrome in adult-onset Still's disease: a report of six cases and a review of the literature. Ann Rheum Dis. 2006;65:1596-1601.
3. Begaud B, Evreux JC, Jouglard J, Lagier G. Imputabilite des effets inattendus ou toxiques des medicaments. Actualisation de la methode utilisee en France. Therapie. 1985;40:111Y118.
4. Begon E, Roujeau JC. Drug hypersensitivity syndrome: DRESS (drug rash with eosinophilia and systemic symptoms). Ann Dermatol Venereol. 2004;131:293-297.
5. Beneton N, Bocquet H, Cosnes A, Revuz J, Roujeau JC. Benefit-risk assessment of acne therapies. Lancet. 1997;349:1252.
6. Bischoff-Ferrari HA, Giovanucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84:18-28.
7. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg. 1996;15: 250-257.
8. Burke AP, Saenger J, Mullick F, Virmani R. Hypersensitivity myocarditis. Arch Pathol Lab Med. 1991;115:764-769.
9. Cantorna MT. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? Proc Soc Exp Biol Med. 2000;223:230-233.
10. Cantorna MT. Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Prog Biophys Mol Biol. 2006;92: 60-64.
11. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood). 2004;229:1136-1142.
12. Cantorna MT, Mahon BD. D-Hormone and the immune system. J Rheumatol Suppl. 2005;76:11-20.
13. Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1-25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr. 2004;80(Suppl):1717S-1720S.
14. Carroll MC, Yueng-Yue KA, Esterly NB, Drolet BA. Drug-induced hypersensitivity syndrome in pediatric patients. Pediatrics. 2001; 108:485-492.
15. Chaiken BH, Goldberg BI, Segal JP. Dilantin sensitivity; report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis. N Engl J Med. 1950;242:897-898.
16. Choi JH, Suh CH, Lee YM, Suh YJ, Lee SK, Kim SS, Nahm DH, Park HS. Serum cytokine profiles in patients with adult-onset Still's disease. J Rheumatol. 2003;30:2422-2427.
17. Choquet-Kastylevsky G, Intrator L, Chenal C, Bocquet H, Revuz J, Roujeau JC. Increased levels of interleukin-5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome. Br J Dermatol. 1998;139:1026-1032.
18. Coombs PR, Gell PG. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell RR, ed. Clinical Aspects of Immunology. Oxford: Oxford University Press; 1968:575-596.
19. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med. 1993;328: 1670-1674.
20. Crispin JC, Martinez-Banos D, Alcocer-Varela J. Adult-onset Still disease as the cause of fever of unknown origin. Medicine (Baltimore). 2005;84:331-337.
21. 3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest. 1998;101:252-262.
22. Dhote R, Simon J, Papo T, Detournay B, Sailler L, Andre MH, Dupond JL, Larroche C, Piette AM, Mechenstock D, Ziza JM, Arlaud J, Labussiere AS, Desvaux A, Baty V, Blanche P, Schaeffer A, Piette JC, Guillevin L, Boissonnas A, Christoforov B. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum. 2003;49:633-639.
23. Dinarello CA. Interleukin-1 and interleukin-18 as mediators of inflammation and the aging process. Am J Clin Nutr. 2006;83: 447S-455S.
24. Eliaszewicz M, Flahault A, Roujeau JC, Fillet AM, Challine D, Mansouri S, Wolkenstein P, Aractingi S, Penso-Assathiany D, Maslo C, Bourgault-Villada I, Chosidow O, Caumes E; Epitox Study Group. Prospective evaluation of risk factors of cutaneous drug reactions to sulfonamides in patients with AIDS. J Am Acad Dermatol. 2002; 47:40-46.
25. Emmenegger U, Schaer DJ, Larroche C, Neftel KA. Haemophagocytic syndromes in adults: current concepts and challenges ahead. Swiss Med Wkly. 2005;135:299-314.
26. Farrel J, Naisbitt DJ, Drummond NS, Depta JP, Vilar FJ, Pirmohamed M, Park BK. Characterization of sulfamethoxazole and sulfamethoxazole metabolite-specific T-cell responses in animals and humans. J Pharmacol Exp Ther. 2003;306:229-237.
27. Fautrel B, Le Moel G, Saint-Marcoux B, Taupin P, Vignes S, Rozenberg S, Koeger AC, Meyer O, Guillevin L, Piette JC, Bourgeois P. Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease. J Rheumatol. 2001;28:322-329.
28. Fautrel B, Zing E, Golmard JL, Le Moel G, Bissery A, Rioux C, Rozenberg S, Piette JC, Bourgeois P. Proposal for a new set of classification criteria for adult-onset Still disease. Medicine (Baltimore). 2002;81:194-200.
29. Fenoglio JJ Jr, McAllister HA Jr, Mullick FG. Drug-related myocarditis. Hum Pathol. 1981;12:900Y907.
30. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. 1988;124:869-871.
31. French A, Weller C. Interstitial myocarditis following the clinical and experimental use of sulfonamide drugs. Pathology. 1942;18:109-122.
32. Froicu M, Cantorna MT. Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol. 2007;8:5.
33. Froicu M, Weaver V, Wynn TA, McDowell MA, Welsh JE, Cantorna MT. A crucial role for vitamin D receptor in experimental inflammatory bowel disease. Mol Endocrinol. 2003;17:2386-2392.
34. Galiuto L, Enriquez-Sarano M, Reeder GS, Tazelaar HD, Li JT, Miller FA, Gleich GJ. Eosinophilic myocarditis manifesting as myocardial infarction: early diagnosis and successful treatment. Mayo Clin Proc. 1997;72:603-610.
35. Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol. 2003;73:213-224.
36. Gravanis MB, Hertzler GL, Franch RH, Stacy LD, Ansari A, Kanter KR, Tazelaar HD, Rodeheffer R, McGregor C. Hypersensitivity myocarditis in heart transplant candidates. J Heart Lung Transplant. 1991;10: 688-697.
37. Haas SJ, Hill R, Krum H, Liew D, Tonkin A, Demos L, Stephan K, McNeil J. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf. 2007;30:47-57.
38. Hari Y, Urwiler A, Hurni M, Yawalkar N, Dahinden C, Wendland T, Braathen LR, Matter L, Pichler WJ. Distinct serum cytokine levels in drug- and measles-induced exanthema. Int Arch Allergy Immunol. 1999;120:225-229.
39. Harris SS. Vitamin D and African-Americans. J Nutr. 2006;136:1126-1129.
40. Hawkins ET, Levine TB, Goss SJ, Moosvi A, Levine AB. Hypersen-sitivity myocarditis in the explanted hearts of transplant recipients: reappraisal of pathologic criteria and their clinical implications. Pathol Annu. 1995;30:287-304
41. Henter JI, Elender G, Ost A. Diagnosis guidelines for hemophagocytic lymphohistiocytosis. The FLH Study Group of the Histiocyte Society. Semin Oncol. 1991;18:29-33.
42. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102:4134-4139.
43. Januzzi JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Malanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005; 95:948-954.
44. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, Roujeau JC. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156:609-611.
45. Kawashima M, Yamamura M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Miyawaki S, Amano T, Takeuchi T, Makino H. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum. 2001;44: 550-560.
46. Killian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet. 1999;354:1841-1845.
47. Knowles SR, Shapiro LE, Shear NH. Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Arch Dermatol. 1996;132:934-939.
48. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention, and management. Drug Saf. 1999; 21:489-501.
49. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet. 2000;356:1587-1591.
50. Kong J, Grando SA, Li YC. Regulation of IL-1 family cytokines IL-1>, IL-1 receptor antagonist, and IL-18 by 1,25-dihydroxyvitamin D3 in primary keratinocytes. J Immunol. 2006;176:3780-3787.
51. Lambotte O, Cacoub P, Costedoat N, Le Moel G, Amoura Z, Piette JC. High ferritin and low glycosylated ferritin may also be a marker of excessive macrophage activation. J Rheumatol. 2003;30:1027-1028.
52. Lambotte O, Costedoat-Chalumeau N, Amoura Z, Piette JC, Cacoub P. Drug-induced hemophagocytosis. Am J Med. 2002;112:592-593.
53. Liu PT, Krutzik SR, Modlin RL. Therapeutic implications of the TLR and VDR partnership. Trends Mol Med. 2007;13:117-124.
54. 3 utilize distinct pathways to suppress IL-12 production and modulate rapid differentiation of human monocytes into CD83 + dendritic cells. J Immunol. 2005;174:2061-2070.
55. Maeno N, Takei S, Imanaka H, Yamamoto K, Kuriwaki K, Kawano Y, Oda H. Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome. Arthritis Rheum. 2004;50: 1935-1938.
56. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jagel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A; PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568-579.
57. Mathieu C, Adorini L. The coming age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med. 2002;8: 174-179.
58. Maubec E, Wolkenstein P, Loriot MA, Wechsler J, Mulot C, Beaune P, Revuz J, Roujeau JC. Minocycline-induced DRESS: evidence for the accumulation of the culprit drug. Dermatology. 2008;216:200-204.
59. Mauri-Hellweg D, Bettens F, Mauri D, Brander C, Hunziker T, Pichler WJ. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin and carbamazepine. J Immunol. 1995;155:462-472.
60. Mazodier K, Marin V, Novick D, Farnarier C, Robitail S, Schleinitz N, Veit V, Paul P, Rubinstein M, Dinarello CA, Harle JR, Kaplanski G. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood. 2005;106:3483-3489.
61. Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick DW, Picler WJ, Pirmohamed M, Park BK. Hypersensitivity reactions to carbamazepine, characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol. 2003;63:732-741.
62. Naisbitt DJ, Farrell J, Wong G, Depta JP, Dodd CC, Hopkins JE, Gibney CA, Chadwick DW, Pichler WJ, Pirmohamed M, Park BK. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol. 2003;111:1393-1403.
63. Naisbitt DJ, Gordon SF, Pirmohamed M, Burkhart C, Cribb AE, Pichler WJ, Park BK. Antigenicity and immunogenicity of sulphametoxazole: demonstration of metabolism-dependant haptenation and T-cell proliferation in-vivo. Br J Pharmacol. 2001;133:295-305.
64. Naisbitt DJ, Gordon SF, Pirmohamed M, Park BK. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf. 2000;23: 483-507.
65. Naito Y, Tsujino T, Fujioka Y, Ohyanagi M, Okamura H, Iwasaki T. Increased circulating interleukin-18 in patients with congestive heart failure. Heart. 2002;88:296-297.
66. Nishio D, Izu K, Kabashima K, Tokura Y. T cell populations propagating in the peripheral blood of patients with drug eruptions. J Dermatol Sci. 2007;48:25-33.
67. Ogata A, Kitano M, Yamanaka J, Yamasaki T, Hashimoto N, Iwasaki T, Hamano T, Fujimoto J, Kakishita E. Interleukin 18 and hepatocyte growth factor in fulminant hepatic failure of adult-onset Still's disease. J Rheumatol. 2003;30:1093-1096.
68. Peyriere H, Dereure O, Breton H, Demoly P, Cociglio M, Blayac JP, Hillaire-Buys D. Network of the French Pharmacovigilance Centers. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2006;155:422-428.
69. Pirmohamed M, Lin K, Chadwick D, Park BK. TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology. 2001;56:890-896.
70. Rieder MJ, Shear NH, Kanee A. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther. 1991;49:13-17.
71. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005;209:123-129.
72. Sabatine MS, Poh KK, Mega JL, Shepard JA, Stone JR, Frosch MP. Case 36-2007: a 31-year-old woman with rash, fever, and hypotension. N Engl J Med. 2007;357:2167-2178.
73. Schaffer SW, Dimayuga ER, Kayes SG. Development and characterization of a model of eosinophil-mediated cardiomyopathy in rats infected with Toxocara canis. Am J Physiol. 1992;262: H1428-H1434.
74. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83:754-759.
75. Seta Y, Kanda T, Tanaka T, Arai M, Sekiguchi K, Yokoyama T, Kurimoto M, Tamura J, Kurabayashi M. Interleukin-18 in patients with congestive heart failure: induction of atrial natriuretic peptide gene expression. Res Commun Mol Pathol Pharmacol. 2000;108:87-95.
76. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest. 1988;82:1826-1832.
77. Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med. 1986;105:179-184.
78. Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol. 2007;156:1045-1092.
79. Slungaard A, Mahoney JR Jr. Bromide-dependant toxicity of eosinophil peroxidase for endothelium and isolated working rat hearts: a model for eosinophilic endocarditis. J Exp Med. 1991;173:117-126.
80. Spear GS. Eosinophilic explant carditis with eosinophilia: hypersensitivity to dobutamine infusion? J Heart Lung Transplant. 1995;14:755-760.
81. Stephensen CB, Marquis GS, Kruzich LA, Douglas SD, Aldrovandi GM, Wilson CM. Vitamin D status in adolescents and young adults with HIV infection. Am J Clin Nutr. 2006;83:1135-1141.
82. Tai PC, Hays DJ, Clark JB, Spry CJ. Toxic effects of human eosinophil products on isolated rat heart cells in vitro. Biochem J. 1982;204:75-80.
83. Takada H, Nomura A, Ohga S, Hara T. Interleukin-18 in hemophagocytic lymphohistiocytosis. Leuk Lymphoma. 2001;42: 21-28.
84. Takkenberg JJM, Czer LSC, Fishbein MC, Luthringer DJ, Quartel AW, Mirocha J, Queral CA, Blanche C, Trento A. Eosinophilic myocarditis in patients awaiting heart transplantation. Crit Care Med. 2004;32: 714-721.
85. Tohyama M, Hashimoto K. Drug-induced hypersensitivity syndrome and human herpesvirus 6 reactivation. Arch Dermatol. 2002;138: 268-269.
86. Tohyama M, Hashimoto K, Yasukawa M, Kimura H, Horikawa T, Nakajima Y, Urano Y, Matsumoto K, Iijima M, Shear NH. Association of human herpes virus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol. 2007;157: 934-940.
87. Tsuge I, Okumura A, Kondo Y, Itomi S, Kakami M, Kawamura M, Nakajima Y, Komatsubara R, Urisu A. Allergen-specific T-cell response in patients with phenytoin hypersensitivity; simultaneous analysis of proliferation and cytokine production by carboxyfluorescein succinimidyl ester (CFSE) dilution assay. Allergol Int. 2007;56: 149-155.
88. Uetrecht J. Drug metabolism by leukocytes and its role in drug-induced lupus and other idiosyncratic drug reactions. Crit Rev Toxicol. 1990; 20:213-235.
89. Vieth R, Kimball S. Vitamin D in congestive heart failure. Am J Clin Nutr. 2006;83:731-732.
90. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med. 1995;155:2285-2290.
91. Woldbaek PR, Sande JB, Strømme TA, Lunde PK, Djurovic S, Lyberg T, Christensen G, TLnnessen T. Daily administration of interleukin-18 causes myocardial dysfunction in healthy mice. Am J Physiol Heart Circ Physiol. 2005;289:H708-H714.
92. Yamamura M, Kawashima M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Morita Y, Ohmoto Y, Makino H. Interferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum. 2001;44:275Y285.
93. Young JD, Peterson CG, Venge P, Cohn ZA. Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature. 1986;321:613-616.
94. 3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol. 2005;35:217-224.